Clinical and Experimental Nephrology · 2018 · 13 citations · 21 references
MedicineNephrologyPediatric NephrologyRenal PathologyRenal PathophysiologyChronic Kidney DiseaseHereditary Kidney DiseasesHereditary Renal DiseasesRenal AssessmentRenal DiseaseRenal Function TestsCkd ProgressionGlomerular Filtration Rate MeasurementRenal SurvivalSubgroup Differences
BACKGROUND: The Mayo Clinic Image Classification (MIC) was proposed as a renal prognosis prediction model for autosomal dominant polycystic kidney disease (ADPKD). MIC is based on the assumption of exponential constant increase in height-adjusted total kidney volume (HtTKV). HtTKV growth rate is calculated by one-time measurement of HtTKV and age. We named it as an age-adjusted HtTKV growth rate (AHTKV-α). AHTKV-α was compared with HtTKV slope measured by at least two HtTKV values. METHODS: Comparison of repeatability between AHTKV-α and HtTKV slope, correlation of subgroups divided according to baseline AHTKV-α and HtTKV slope with disease manifestations, estimated glomerular filtration rate (eGFR) slope, and renal survival were analyzed in 296 patients with ADPKD. PKD genotype influences were compared between AHTKV-α and HtTKV slope in 88 patients with characterized PKD mutations. RESULTS: Absolute differences between baseline and follow-up measures were significantly larger for the HtTKV slope than for AHTKV-α (P < 0.0001). From baseline AHTKV-α-based subgroups A-E according to MIC, disease manifestations occurred earlier and future eGFR slopes became steeper (P < 0.0001). Multivariate hazard ratios of renal survival differed significantly among baseline AHTKV-α-based subgroups. Inter-subgroup differences in these predictors were less evident during baseline HtTKV slope-based classification. AHTKV-α values, but not HtTKV slopes, were significantly higher for PKD1 mutation carriers than for PKD2 mutation carriers (P < 0.0001). CONCLUSION: MIC is a good renal prediction model applicable to Japanese patients also. AHTKV-α can be a more sensitive and reliable indicator in TKV growth rate than HtTKV slope.
21
Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst et al. · New England Journal of Medicine · 2012 · 1.6K citations · Full text
Medicine, Nephrology, Pharmacology +14
Volume Progression in Polycystic Kidney Disease
Jared J. Grantham, Vicente E. Torres, Arlene B. Chapman et al. · New England Journal of Medicine · 2006 · 792 citations · Full text
Medicine, Nephrology, Radiology +16
Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease
Gerd Walz, Klemens Budde, Marwan Mannaa et al. · New England Journal of Medicine · 2010 · 577 citations · Full text